GRP
RARE icon

Global Retirement Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Global Retirement Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.2K Buy
52
+41
+373% +$1.35K ﹤0.01% 3853
2025
Q3 		$331 Sell
11
-34
-76% -$1.02K ﹤0.01% 3694
2025
Q2 		$1.64K Buy
+45
New +$1.62K ﹤0.01% 3308
2024
Q4 		$1.89K Hold
45
– – ﹤0.01% 3090
2024
Q3 		$2.5K Hold
45
– – ﹤0.01% 2863
2024
Q2 		$1.85K Hold
45
– – ﹤0.01% 2991
2024
Q1 		$2.1K Hold
45
– – ﹤0.01% 2733
2023
Q4 		$1.98K Buy
45
+8
+22% +$310 ﹤0.01% 2677
2023
Q3 		$1.27K Sell
37
-15
-29% -$594 ﹤0.01% 2702
2023
Q2 		$2.4K Hold
52
– – ﹤0.01% 2474
2023
Q1 		$2.25K Sell
52
-3
-5% -$129 ﹤0.01% 2462
2022
Q4 		$2.55K Buy
55
+31
+129% +$1.22K ﹤0.01% 2269
2022
Q3 		$1K Sell
24
-4
-14% -$206 ﹤0.01% 2556
2022
Q2 		$2K Hold
28
– – ﹤0.01% 2252
2022
Q1 		$1K Buy
+28
New +$1.95K ﹤0.01% 2490

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Global Retirement Partners's RARE Position: Q4 2025 in Review

Global Retirement Partners increased its Ultragenyx Pharmaceutical (RARE) stake by 373% in Q4 2025, buying an estimated $1.35K and bringing the position to 52 shares worth $1.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3853.

Global Retirement Partners first reported a position in RARE in Q1 2022 and has held it in 15 quarters since. The position peaked at $2.55K in Q4 2022. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • Global Retirement Partners held 52 shares of Ultragenyx Pharmaceutical worth $1.2K as of Q4 2025.
  • Global Retirement Partners bought 41 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $1.35K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Global Retirement Partners's portfolio in Q4 2025, its #3853 holding.
  • Global Retirement Partners first reported a position in Ultragenyx Pharmaceutical in Q1 2022 and has held it in 15 quarters since.
  • Global Retirement Partners's Ultragenyx Pharmaceutical position peaked at $2.55K in Q4 2022.
  • 287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Global Retirement Partners's 13F filing for Q4 2025, filed 6 Feb 2026.